华北制药(600812) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 was CNY 2,329,115,080.76, a decrease of 15.04% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 30,479,245.32, an increase of 2,035.13% year-on-year[2] - Year-to-date net profit attributable to shareholders reached CNY 102,463,641.21, reflecting a significant increase of 266.29% compared to the previous year[2] - Total operating revenue for Q3 2024 was approximately CNY 7.56 billion, a decrease of 5.2% from CNY 7.97 billion in Q3 2023[15] - Net profit for Q3 2024 was approximately CNY 146.44 million, compared to CNY 50.38 million in Q3 2023, representing a significant increase of 190.5%[16] - The company reported a total profit of approximately CNY 222.98 million for Q3 2024, compared to CNY 127.08 million in Q3 2023, reflecting a year-over-year increase of 75.4%[16] - The total profit for the first three quarters of 2024 was CNY 138,808,543.58, a decrease of 57.5% compared to CNY 326,774,380.40 in 2023[23] Earnings Per Share - Basic earnings per share for Q3 2024 was CNY 0.018, up 1,700.00% from the same period last year[3] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.060, up from CNY 0.016 in Q3 2023[17] Assets and Liabilities - Total assets as of the end of the reporting period were CNY 21,706,791,241.09, representing a 3.58% increase from the end of the previous year[3] - As of September 30, 2024, current assets totaled RMB 8,673,534,666.03, an increase from RMB 8,017,591,063.58 at the end of 2023, representing an increase of approximately 8.2%[11] - Total liabilities amounted to RMB 15,101,207,705.84, compared to RMB 14,686,289,888.70 at the end of 2023, marking an increase of about 2.8%[13] - The company's total assets reached RMB 21,706,791,241.09, up from RMB 20,956,700,067.79, indicating a growth of approximately 3.6%[13] - The total liabilities rose to 13,215,984,063.55 CNY, compared to 11,596,014,561.77 CNY, indicating an increase of approximately 14%[20] Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 78.26% to CNY 1,058,395,635.41[5] - Cash flow from operating activities for the first nine months of 2024 was approximately CNY 1.06 billion, compared to CNY 593.73 million in the same period of 2023, indicating a substantial improvement[17] - The cash flow from financing activities generated a net inflow of 279,341,087.34 CNY, a turnaround from a net outflow of -305,232,319.28 CNY in the previous year[18] - The company recorded a net cash outflow from investing activities of CNY -86,530,136.15 in 2024, compared to a net inflow of CNY 265,246,558.21 in 2023[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 80,230[6] - Major shareholders include Jizhong Energy Co., Ltd. with a 24.08% stake and Huabei Pharmaceutical Group Co., Ltd. with a 19.90% stake[7] Cost Management - The company implemented cost control measures, leading to a reduction in procurement costs and improved profitability[5] - Total operating costs decreased to approximately CNY 7.40 billion, down 5.9% from CNY 7.86 billion in the same period last year[15] - Sales expenses decreased to approximately CNY 1.05 billion, down 21.6% from CNY 1.34 billion in Q3 2023[15] - The company reported a decrease in sales expenses to CNY 402,179,650.16 in 2024, down 33.3% from CNY 603,321,346.48 in 2023[22] Research and Development - Research and development expenses increased to approximately CNY 251.67 million, up 22.5% from CNY 205.36 million in Q3 2023[15] - Research and development expenses increased to CNY 48,995,831.25 in 2024, up 24.5% from CNY 39,246,045.74 in 2023[22] Other Financial Metrics - The company reported non-recurring gains of CNY 2,273,195.66 for Q3 2024, contributing to overall profitability[4] - Tax expenses for Q3 2024 were approximately CNY 76.54 million, slightly down from CNY 76.70 million in Q3 2023[16] - Other comprehensive income after tax for Q3 2024 was a loss of CNY 150,201.56, compared to a gain of CNY 1.61 million in Q3 2023[16]